Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1371-1377

  Motzer, Robert J ^a   Hutson, Thomas E ^c   Olsen, Mark R ^d   Hudes, Gary R ^e   Burke, John M ^f   Edenfield, William J ^g   Wilding, George ^h   Agarwal, Neeraj ⁱ   Thompson, John A ^j   Cella, David ^k   Bello, Akintunde ^b   Korytowsky, Beata ^b   Yuan, Jinyu ^b   Valota, Olga ^l   Martell, Bridget ^b   Hariharan, Subramanian ^b   Figlin, Robert A ^m  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Pfizer Ltd   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Cancer Care Associates   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f ROCKY MOUNTAIN CANCER CENTERS   (United States)

^g Cancer Centers of the Carolinas   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l PFIZER INC   (United States)

^m CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

N DEETHYLSUNITINIB; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CONSTIPATION; CONTINUOUS DAILY DOSING; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DEMYELINATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART ARREST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INTERMITTENT SCHEDULE; INTESTINE PERFORATION; ISCHEMIC CARDIOMYOPATHY; KIDNEY CARCINOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; VOMITING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84860355062     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.4133     Document Type: Article

References (16)

1. Chow LQ, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25:884-896, 2007 (Pubitemid 350002890)
2. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
3. Escudier B, Roigas J, Gillessen S, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075, 2009
4. Barrios CH, Hernandez-Barajas D, Brown MP, et al: Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118:1252-1259, 2012
5. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
6. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002 (Pubitemid 34032623)
7. Bello CL, Sherman L, Zhou J, et al: Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358, 2006
8. Cella D, Yount S, Du H, et al: Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4:191-199, 2006 (Pubitemid 43890980)
9. Cella D, Yount S, Brucker PS, et al: Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10:285-293, 2007 (Pubitemid 47077253)
10. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993 (Pubitemid 23071057)
11. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
12. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
13. Bjarnson GA, Khalil B, Williams R, et al: Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data. J Clin Oncol 29, 2011 (suppl 7; abstr 356)
14. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
15. Négrier S, Gravis G, Pérol D, et al: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase 2 trial. Lancet Oncol 12:673-680, 2011
16. Rini BI, Szczylik C, Tannir NM, et al: AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29, 2011 (suppl 7; abstr 309)